Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report

Carla Ripamonti, Chiara Ticozzi, Ernesto Zecca, Carlos H. Rodriguez, Franco De Conno

Research output: Contribution to journalArticle

Abstract

Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.

Original languageEnglish
Pages (from-to)413-415
Number of pages3
JournalTumori
Volume82
Issue number4
Publication statusPublished - Jul 1996

Fingerprint

Ketorolac
Subcutaneous Infusions
Neuralgia
Opioid Analgesics
Non-Narcotic Analgesics
Pharmaceutical Preparations
Visceral Pain
Anticonvulsants
Analgesia
Antidepressive Agents
Analgesics
Stomach
Anti-Inflammatory Agents
Therapeutics
Kidney
Cancer Pain
Neoplasms

Keywords

  • cancer
  • continuous subcutaneous infusion
  • ketorolac tromethamine
  • neuropathic pain

ASJC Scopus subject areas

  • Cancer Research

Cite this

Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report. / Ripamonti, Carla; Ticozzi, Chiara; Zecca, Ernesto; Rodriguez, Carlos H.; De Conno, Franco.

In: Tumori, Vol. 82, No. 4, 07.1996, p. 413-415.

Research output: Contribution to journalArticle

@article{5f69f68300d04543b474f5a8a26f5958,
title = "Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report",
abstract = "Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.",
keywords = "cancer, continuous subcutaneous infusion, ketorolac tromethamine, neuropathic pain",
author = "Carla Ripamonti and Chiara Ticozzi and Ernesto Zecca and Rodriguez, {Carlos H.} and {De Conno}, Franco",
year = "1996",
month = "7",
language = "English",
volume = "82",
pages = "413--415",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report

AU - Ripamonti, Carla

AU - Ticozzi, Chiara

AU - Zecca, Ernesto

AU - Rodriguez, Carlos H.

AU - De Conno, Franco

PY - 1996/7

Y1 - 1996/7

N2 - Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.

AB - Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.

KW - cancer

KW - continuous subcutaneous infusion

KW - ketorolac tromethamine

KW - neuropathic pain

UR - http://www.scopus.com/inward/record.url?scp=0029828804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029828804&partnerID=8YFLogxK

M3 - Article

C2 - 8890983

AN - SCOPUS:0029828804

VL - 82

SP - 413

EP - 415

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -